Global Neuromuscualr Disease Therapeutics Market - 2025 -2033
Global Neuromuscular Disease Therapeutics Market: Industry Outlook
The global neuromuscular disease therapeutics market reached US$ 11.89 billion in 2023, with a rise of US$ 13.70 billion in 2024, and is expected to reach US$ 45.62 billion by 2033, growing at a CAGR of 14.4% during the forecast period 2025-2033.
The neuromuscular disease therapeutics market is expanding as advances in genetic medicine and precision therapies redefine treatment possibilities for rare, debilitating disorders. Spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD) currently dominate the market, supported by high-impact approvals such as Spinraza, Zolgensma, Evrysdi, and Elevidys, which have demonstrated both clinical efficacy and commercial success. Growing adoption of newborn screening programs, particularly for SMA, is increasing the number of patients identified at a presymptomatic stage, where treatment can deliver the greatest benefit.
At the same time, drug developers face challenges in scaling manufacturing for viral vector–based therapies and addressing long-term durability and safety questions, which in turn is driving investment in next-generation delivery systems, improved analytics, and alternative modalities. Regulatory frameworks such as orphan drug incentives, priority reviews, and accelerated approvals continue to encourage innovation, while payers and health systems are navigating the complexities of access and affordability for ultra-high-cost therapies.
Dynamics: Drivers & Restraints
Driver: Breakthrough Approvals Validating New Modalities
Breakthrough approvals are reshaping the neuromuscular disease therapeutics market by proving that advanced modalities can deliver real, disease-modifying outcomes. Treatments such as Spinraza, Zolgensma, Evrysdi, and Elevidys have moved the field beyond symptomatic care, showing that antisense oligonucleotides, gene therapies, and splicing modulators can meaningfully alter disease progression in conditions like spinal muscular atrophy and Duchenne muscular dystrophy. These landmark approvals not only expand treatment options for patients but also build confidence among regulators, payers, and clinicians, creating a more favorable environment for pipeline therapies.
By validating new scientific approaches and attracting sustained investment, they are accelerating innovation and positioning neuromuscular therapeutics as a leading area of growth within rare disease and genetic medicine.
Restraint: Manufacturing & Scalability Challenges
Manufacturing and scalability challenges remain a major restraint for the neuromuscular disease therapeutics market. Advanced modalities such as gene therapies, antisense oligonucleotides, and other complex biologics require sophisticated processes, specialized facilities, and rigorous quality control, all of which drive up production costs and limit scalability. Current capacity constraints often result in supply shortages, long lead times, and significant pricing pressures that impact patient access and slow adoption across global markets.
Segmentation Analysis
The global neuromuscular disease therapeutics market is segmented based on therapy, disease type, route of administration, distribution channel, and region.
Gene Therapies:
The gene therapies segment is estimated to have 42.8% of the neuromuscular disease therapeutics market share.
Gene therapies are expected to maintain a dominant position in the neuromuscular disease therapeutics market due to their potential to address the root genetic causes of disease rather than only managing symptoms. Unlike traditional treatments that require continuous administration, gene therapies are often designed as one-time or infrequent interventions that can deliver durable, long-lasting benefits. This unique value proposition has led to strong adoption among clinicians and patients, as well as significant support from regulators through priority review and orphan drug designations.
Moreover, the high unmet need in rare neuromuscular disorders, coupled with the ability of gene therapies to significantly improve survival and functional outcomes, reinforces their competitive advantage. Although high costs and manufacturing complexities remain challenges, ongoing investment in scalable production platforms and broader newborn screening programs is expected to expand patient access. As pipelines mature and additional indications are targeted, gene therapies are set to lead revenue contribution and drive overall market growth in neuromuscular disease therapeutics.
Geographical Share Analysis
The North America neuromuscular disease therapeutics market was valued at 42.1% market share in 2024
North America is expected to dominate the neuromuscular disease therapeutics market due to its strong combination of advanced healthcare infrastructure, favorable regulatory frameworks, and early adoption of innovative therapies. The region benefits from extensive newborn screening programs, particularly for conditions such as spinal muscular atrophy, which enable earlier diagnosis and timely intervention. High levels of investment in research and development, coupled with the presence of leading biopharmaceutical companies and academic research centers, ensure a steady flow of innovation and clinical trial activity.
Additionally, supportive policies such as orphan drug incentives and priority review pathways accelerate approvals, while relatively higher healthcare spending and established reimbursement systems facilitate access to high-cost therapies. Together, these factors position North America as the largest and most influential market for neuromuscular disease therapeutics, setting the pace for global adoption.
Major Players
The major players in the neuromuscular disease therapeutics market include Novartis Pharmaceuticals Corporation, AbbVie Inc., Corium, LLC, AstraZeneca, Argenx, Biogen, Grifols, Nippon Shinyaku Co., Ltd., Takeda Pharmaceutical Company Limited, Sarepta Therapeutics, Inc., among others.
Key Developments
The global neuromuscular disease therapeutics market reached US$ 11.89 billion in 2023, with a rise of US$ 13.70 billion in 2024, and is expected to reach US$ 45.62 billion by 2033, growing at a CAGR of 14.4% during the forecast period 2025-2033.
The neuromuscular disease therapeutics market is expanding as advances in genetic medicine and precision therapies redefine treatment possibilities for rare, debilitating disorders. Spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD) currently dominate the market, supported by high-impact approvals such as Spinraza, Zolgensma, Evrysdi, and Elevidys, which have demonstrated both clinical efficacy and commercial success. Growing adoption of newborn screening programs, particularly for SMA, is increasing the number of patients identified at a presymptomatic stage, where treatment can deliver the greatest benefit.
At the same time, drug developers face challenges in scaling manufacturing for viral vector–based therapies and addressing long-term durability and safety questions, which in turn is driving investment in next-generation delivery systems, improved analytics, and alternative modalities. Regulatory frameworks such as orphan drug incentives, priority reviews, and accelerated approvals continue to encourage innovation, while payers and health systems are navigating the complexities of access and affordability for ultra-high-cost therapies.
Dynamics: Drivers & Restraints
Driver: Breakthrough Approvals Validating New Modalities
Breakthrough approvals are reshaping the neuromuscular disease therapeutics market by proving that advanced modalities can deliver real, disease-modifying outcomes. Treatments such as Spinraza, Zolgensma, Evrysdi, and Elevidys have moved the field beyond symptomatic care, showing that antisense oligonucleotides, gene therapies, and splicing modulators can meaningfully alter disease progression in conditions like spinal muscular atrophy and Duchenne muscular dystrophy. These landmark approvals not only expand treatment options for patients but also build confidence among regulators, payers, and clinicians, creating a more favorable environment for pipeline therapies.
By validating new scientific approaches and attracting sustained investment, they are accelerating innovation and positioning neuromuscular therapeutics as a leading area of growth within rare disease and genetic medicine.
Restraint: Manufacturing & Scalability Challenges
Manufacturing and scalability challenges remain a major restraint for the neuromuscular disease therapeutics market. Advanced modalities such as gene therapies, antisense oligonucleotides, and other complex biologics require sophisticated processes, specialized facilities, and rigorous quality control, all of which drive up production costs and limit scalability. Current capacity constraints often result in supply shortages, long lead times, and significant pricing pressures that impact patient access and slow adoption across global markets.
Segmentation Analysis
The global neuromuscular disease therapeutics market is segmented based on therapy, disease type, route of administration, distribution channel, and region.
Gene Therapies:
The gene therapies segment is estimated to have 42.8% of the neuromuscular disease therapeutics market share.
Gene therapies are expected to maintain a dominant position in the neuromuscular disease therapeutics market due to their potential to address the root genetic causes of disease rather than only managing symptoms. Unlike traditional treatments that require continuous administration, gene therapies are often designed as one-time or infrequent interventions that can deliver durable, long-lasting benefits. This unique value proposition has led to strong adoption among clinicians and patients, as well as significant support from regulators through priority review and orphan drug designations.
Moreover, the high unmet need in rare neuromuscular disorders, coupled with the ability of gene therapies to significantly improve survival and functional outcomes, reinforces their competitive advantage. Although high costs and manufacturing complexities remain challenges, ongoing investment in scalable production platforms and broader newborn screening programs is expected to expand patient access. As pipelines mature and additional indications are targeted, gene therapies are set to lead revenue contribution and drive overall market growth in neuromuscular disease therapeutics.
Geographical Share Analysis
The North America neuromuscular disease therapeutics market was valued at 42.1% market share in 2024
North America is expected to dominate the neuromuscular disease therapeutics market due to its strong combination of advanced healthcare infrastructure, favorable regulatory frameworks, and early adoption of innovative therapies. The region benefits from extensive newborn screening programs, particularly for conditions such as spinal muscular atrophy, which enable earlier diagnosis and timely intervention. High levels of investment in research and development, coupled with the presence of leading biopharmaceutical companies and academic research centers, ensure a steady flow of innovation and clinical trial activity.
Additionally, supportive policies such as orphan drug incentives and priority review pathways accelerate approvals, while relatively higher healthcare spending and established reimbursement systems facilitate access to high-cost therapies. Together, these factors position North America as the largest and most influential market for neuromuscular disease therapeutics, setting the pace for global adoption.
Major Players
The major players in the neuromuscular disease therapeutics market include Novartis Pharmaceuticals Corporation, AbbVie Inc., Corium, LLC, AstraZeneca, Argenx, Biogen, Grifols, Nippon Shinyaku Co., Ltd., Takeda Pharmaceutical Company Limited, Sarepta Therapeutics, Inc., among others.
Key Developments
- In March 2024, the U.S. approved Ultomiris (ravulizumab-cwvz) as the first and only long-acting C5 complement inhibitor for treating adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
- In October 2024, AbbVie announced that the U.S. Food and Drug Administration (FDA) approved VYALEV (foscarbidopa and foslevodopa), marking it as the first and only 24-hour subcutaneous infusion of a levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson’s disease.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy
2.4. Snippet by Disease Type
2.5. Snippet by Route of Administration
2.6. Snippet by Distribution Channel
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Breakthrough Approvals Validating New Modalities
3.1.1.2. Rising Prevalence and Improved Diagnosis
3.1.2. Restraints
3.1.2.1. Manufacturing & Scalability Challenges
3.1.2.2. High Costs of Therapies
3.1.3. Opportunity
3.1.3.1. Expansion of Indications and Patient Populations
3.1.3.2. Geographic Expansion into Emerging Markets
3.1.4. Impact Analysis
4. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: BY THERAPY
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
5.1.2. Market Attractiveness Index, By Therapy
5.2. Gene Therapies*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Antisense Oligonucleotides (ASOs)
5.4. Small-Molecule Splicing Modulators
5.5. Monoclonal Antibodies & Complement Inhibitors
5.6. Others
6. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: BY DISEASE TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Amyotrophic Lateral Sclerosis (ALS)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Charcot-Marie-Tooth disease
6.4. Multiple Sclerosis
6.5. Muscular Dystrophy
6.6. Myasthenia Gravis
6.7. Myopathy
6.8. Myositis
6.9. Peripheral Neuropathy
6.10. Spinal Muscular Atrophy
6.11. Others
7. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Intravenous (IV) Infusion
7.4. Subcutaneous
7.5. Others
8. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail / Specialty Pharmacies
8.4. Others
9. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10. INTRODUCTION
10.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.1. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking
12. COMPANY PROFILES
12.1. Novartis Pharmaceuticals Corporation*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.4.4. SWOT Analysis
12.2. AbbVie Inc.
12.3. Corium, LLC
12.4. AstraZeneca
12.5. argenx
12.6. Biogen
12.7. Grifols
12.8. Nippon Shinyaku Co. Ltd.
12.9. Takeda Pharmaceutical Company Limited
12.10. Sarepta Therapeutics, Inc. (LIST NOT EXHAUSTIVE)
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy
2.4. Snippet by Disease Type
2.5. Snippet by Route of Administration
2.6. Snippet by Distribution Channel
2.7. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Breakthrough Approvals Validating New Modalities
3.1.1.2. Rising Prevalence and Improved Diagnosis
3.1.2. Restraints
3.1.2.1. Manufacturing & Scalability Challenges
3.1.2.2. High Costs of Therapies
3.1.3. Opportunity
3.1.3.1. Expansion of Indications and Patient Populations
3.1.3.2. Geographic Expansion into Emerging Markets
3.1.4. Impact Analysis
4. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest largest-selling Brand
4.1.3. Market leaders with established products & Services
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics
5. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: BY THERAPY
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
5.1.2. Market Attractiveness Index, By Therapy
5.2. Gene Therapies*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Antisense Oligonucleotides (ASOs)
5.4. Small-Molecule Splicing Modulators
5.5. Monoclonal Antibodies & Complement Inhibitors
5.6. Others
6. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: BY DISEASE TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
6.1.2. Market Attractiveness Index, By Disease Type
6.2. Amyotrophic Lateral Sclerosis (ALS)*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Charcot-Marie-Tooth disease
6.4. Multiple Sclerosis
6.5. Muscular Dystrophy
6.6. Myasthenia Gravis
6.7. Myopathy
6.8. Myositis
6.9. Peripheral Neuropathy
6.10. Spinal Muscular Atrophy
6.11. Others
7. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
7.1.2. Market Attractiveness Index, By Route of Administration
7.2. Oral*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Intravenous (IV) Infusion
7.4. Subcutaneous
7.5. Others
8. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail / Specialty Pharmacies
8.4. Others
9. GLOBAL NEUROMUSCULAR DISEASE THERAPEUTICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
10. INTRODUCTION
10.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.1. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. U.K.
10.3.7.3. France
10.3.7.4. Spain
10.3.7.5. Italy
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
11.1. Competitive Overview and Key Market Players
11.2. Market Share Analysis and Positioning Matrix
11.3. Strategic Partnerships, Mergers & Acquisitions
11.4. Key Developments in Product Portfolios and Innovations
11.5. Company Benchmarking
12. COMPANY PROFILES
12.1. Novartis Pharmaceuticals Corporation*
12.1.1. Company Overview
12.1.2. Product Portfolio
12.1.2.1. Product Description
12.1.2.2. Product Key Performance Indicators (KPIs)
12.1.2.3. Historic and Forecasted Product Sales
12.1.2.4. Product Sales Volume
12.1.3. Financial Overview
12.1.3.1. Company Revenue
12.1.3.2. Geographical Revenue Shares
12.1.3.3. Revenue Forecasts
12.1.4. Key Developments
12.1.4.1. Mergers & Acquisitions
12.1.4.2. Key Product Development Activities
12.1.4.3. Regulatory Approvals, etc.
12.1.4.4. SWOT Analysis
12.2. AbbVie Inc.
12.3. Corium, LLC
12.4. AstraZeneca
12.5. argenx
12.6. Biogen
12.7. Grifols
12.8. Nippon Shinyaku Co. Ltd.
12.9. Takeda Pharmaceutical Company Limited
12.10. Sarepta Therapeutics, Inc. (LIST NOT EXHAUSTIVE)
13. ASSUMPTIONS AND RESEARCH METHODOLOGY
13.1. Data Collection Methods
13.2. Data Triangulation
13.3. Forecasting Techniques
13.4. Data Verification and Validation
14. APPENDIX
14.1. About Us and Services
14.2. Contact Us
LIST OF TABLES
Table 1 Global Neuromuscular Disease Therapeutics Market Value, By Therapy, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Neuromuscular Disease Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Neuromuscular Disease Therapeutics Market Value, By Therapy, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 8 Global Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 10 Global Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 12 Global Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 14 Global Neuromuscular Disease Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Neuromuscular Disease Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 17 North America Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 18 North America Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 19 North America Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 North America Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 27 Europe Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 28 Europe Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 29 Europe Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 30 Europe Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 32 South America Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 33 South America Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 34 South America Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 35 South America Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Novartis Pharmaceuticals Corporation: Overview
Table 42 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 43 Novartis Pharmaceuticals Corporation: Key Developments
Table 44 AbbVie Inc.: Overview
Table 45 AbbVie Inc.: Product Portfolio
Table 46 AbbVie Inc.: Key Developments
Table 47 Corium, LLC: Overview
Table 48 Corium, LLC: Product Portfolio
Table 49 Corium, LLC: Key Developments
Table 50 AstraZeneca: Overview
Table 51 AstraZeneca: Product Portfolio
Table 52 AstraZeneca: Key Developments
Table 53 argenx: Overview
Table 54 argenx: Product Portfolio
Table 55 argenx: Key Developments
Table 56 Biogen: Overview
Table 57 Biogen: Product Portfolio
Table 58 Biogen: Key Developments
Table 59 Grifols: Overview
Table 60 Grifols: Product Portfolio
Table 61 Grifols: Key Developments
Table 62 Nippon Shinyaku Co. Ltd.: Overview
Table 63 Nippon Shinyaku Co. Ltd.: Product Portfolio
Table 64 Nippon Shinyaku Co. Ltd.: Key Developments
Table 65 Takeda Pharmaceutical Company Limited: Overview
Table 66 Takeda Pharmaceutical Company Limited: Product Portfolio
Table 67 Takeda Pharmaceutical Company Limited: Key Developments
Table 68 Sarepta Therapeutics, Inc.: Overview
Table 69 Sarepta Therapeutics, Inc.: Product Portfolio
Table 70 Sarepta Therapeutics, Inc.: Key Developments
Table 1 Global Neuromuscular Disease Therapeutics Market Value, By Therapy, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Neuromuscular Disease Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Neuromuscular Disease Therapeutics Market Value, By Therapy, 2025, 2029 & 2033 (US$ Billion)
Table 7 Global Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 8 Global Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2025, 2029 & 2033 (US$ Billion)
Table 9 Global Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 10 Global Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)
Table 11 Global Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 12 Global Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 13 Global Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 14 Global Neuromuscular Disease Therapeutics Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 15 Global Neuromuscular Disease Therapeutics Market Value, By Region, 2022-2033 (US$ Billion)
Table 16 North America Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 17 North America Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 18 North America Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 19 North America Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 North America Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 25 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 26 Europe Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 27 Europe Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 28 Europe Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 29 Europe Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 30 Europe Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 31 South America Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 32 South America Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 33 South America Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 34 South America Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 35 South America Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 36 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Therapy, 2022-2033 (US$ Billion)
Table 37 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Disease Type, 2022-2033 (US$ Billion)
Table 38 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Route of Administration, 2022-2033 (US$ Billion)
Table 39 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 40 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, By Country, 2022-2033 (US$ Billion)
Table 41 Novartis Pharmaceuticals Corporation: Overview
Table 42 Novartis Pharmaceuticals Corporation: Product Portfolio
Table 43 Novartis Pharmaceuticals Corporation: Key Developments
Table 44 AbbVie Inc.: Overview
Table 45 AbbVie Inc.: Product Portfolio
Table 46 AbbVie Inc.: Key Developments
Table 47 Corium, LLC: Overview
Table 48 Corium, LLC: Product Portfolio
Table 49 Corium, LLC: Key Developments
Table 50 AstraZeneca: Overview
Table 51 AstraZeneca: Product Portfolio
Table 52 AstraZeneca: Key Developments
Table 53 argenx: Overview
Table 54 argenx: Product Portfolio
Table 55 argenx: Key Developments
Table 56 Biogen: Overview
Table 57 Biogen: Product Portfolio
Table 58 Biogen: Key Developments
Table 59 Grifols: Overview
Table 60 Grifols: Product Portfolio
Table 61 Grifols: Key Developments
Table 62 Nippon Shinyaku Co. Ltd.: Overview
Table 63 Nippon Shinyaku Co. Ltd.: Product Portfolio
Table 64 Nippon Shinyaku Co. Ltd.: Key Developments
Table 65 Takeda Pharmaceutical Company Limited: Overview
Table 66 Takeda Pharmaceutical Company Limited: Product Portfolio
Table 67 Takeda Pharmaceutical Company Limited: Key Developments
Table 68 Sarepta Therapeutics, Inc.: Overview
Table 69 Sarepta Therapeutics, Inc.: Product Portfolio
Table 70 Sarepta Therapeutics, Inc.: Key Developments
LIST OF FIGURES
Figure 1 Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 3 Global Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 4 Global Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 6 Global Neuromuscular Disease Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Therapy, 2023-2033 (%)
Figure 8 Gene Therapies Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Antisense Oligonucleotides (ASOs) Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 10 Small-Molecule Splicing Modulators Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 11 Monoclonal Antibodies & Complement Inhibitors Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 12 Others Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 14 Amyotrophic lateral sclerosis (ALS) Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Charcot-Marie-Tooth disease Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 16 Multiple Sclerosis Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Muscular Dystrophy Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 Myasthenia Gravis Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 19 Myopathy Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 20 Myositis Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 21 Peripheral Neuropathy Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 Spinal Muscular Atrophy Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 25 Oral Route of Administration in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 26 Intravenous (IV) Infusion Route of Administration in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 27 Subcutaneous Route of Administration in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 28 Others Route of Administration in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 29 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 30 Hospital Pharmacies Distribution Channel in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 31 Retail / Specialty Pharmacies Distribution Channel in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 32 Others Distribution Channel in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 33 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 34 North America Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 35 North America Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 36 North America Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 37 North America Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 38 North America Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 39 North America Neuromuscular Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 40 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 41 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 42 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 43 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 44 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 46 Europe Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 47 Europe Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 48 Europe Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 49 Europe Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 50 Europe Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 51 Europe Neuromuscular Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 52 South America Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 53 South America Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 54 South America Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 55 South America Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 56 South America Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 57 South America Neuromuscular Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 58 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 59 Middle East and Africa Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 60 Middle East and Africa Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 61 Middle East and Africa Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 62 Middle East and Africa Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 63 Novartis Pharmaceuticals Corporation: Financials
Figure 64 AbbVie Inc.: Financials
Figure 65 Corium, LLC: Financials
Figure 66 AstraZeneca: Financials
Figure 67 argenx: Financials
Figure 68 Biogen: Financials
Figure 69 Grifols: Financials
Figure 70 Nippon Shinyaku Co. Ltd.: Financials
Figure 71 Takeda Pharmaceutical Company Limited: Financials
Figure 72 Sarepta Therapeutics, Inc.: Financials
Figure 1 Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 3 Global Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 4 Global Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 5 Global Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 6 Global Neuromuscular Disease Therapeutics Market Share, By Region, 2024 & 2033 (%)
Figure 7 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Therapy, 2023-2033 (%)
Figure 8 Gene Therapies Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 9 Antisense Oligonucleotides (ASOs) Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 10 Small-Molecule Splicing Modulators Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 11 Monoclonal Antibodies & Complement Inhibitors Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 12 Others Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 13 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Disease Type, 2023-2033 (%)
Figure 14 Amyotrophic lateral sclerosis (ALS) Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 15 Charcot-Marie-Tooth disease Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 16 Multiple Sclerosis Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 17 Muscular Dystrophy Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 18 Myasthenia Gravis Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 19 Myopathy Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 20 Myositis Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 21 Peripheral Neuropathy Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 22 Spinal Muscular Atrophy Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 23 Others Disease Type in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 24 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)
Figure 25 Oral Route of Administration in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 26 Intravenous (IV) Infusion Route of Administration in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 27 Subcutaneous Route of Administration in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 28 Others Route of Administration in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 29 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 30 Hospital Pharmacies Distribution Channel in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 31 Retail / Specialty Pharmacies Distribution Channel in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 32 Others Distribution Channel in Global Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 33 Global Neuromuscular Disease Therapeutics Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 34 North America Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 35 North America Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 36 North America Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 37 North America Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 38 North America Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 39 North America Neuromuscular Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 40 Asia-Pacific Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 41 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 42 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 43 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 44 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 45 Asia-Pacific Neuromuscular Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 46 Europe Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 47 Europe Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 48 Europe Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 49 Europe Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 50 Europe Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 51 Europe Neuromuscular Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 52 South America Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 53 South America Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 54 South America Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 55 South America Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 56 South America Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 57 South America Neuromuscular Disease Therapeutics Market Share, By Country, 2024 & 2033 (%)
Figure 58 Middle East and Africa Neuromuscular Disease Therapeutics Market Value, 2022-2033 (US$ Billion)
Figure 59 Middle East and Africa Neuromuscular Disease Therapeutics Market Share, By Therapy, 2024 & 2033 (%)
Figure 60 Middle East and Africa Neuromuscular Disease Therapeutics Market Share, By Disease Type, 2024 & 2033 (%)
Figure 61 Middle East and Africa Neuromuscular Disease Therapeutics Market Share, By Route of Administration, 2024 & 2033 (%)
Figure 62 Middle East and Africa Neuromuscular Disease Therapeutics Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 63 Novartis Pharmaceuticals Corporation: Financials
Figure 64 AbbVie Inc.: Financials
Figure 65 Corium, LLC: Financials
Figure 66 AstraZeneca: Financials
Figure 67 argenx: Financials
Figure 68 Biogen: Financials
Figure 69 Grifols: Financials
Figure 70 Nippon Shinyaku Co. Ltd.: Financials
Figure 71 Takeda Pharmaceutical Company Limited: Financials
Figure 72 Sarepta Therapeutics, Inc.: Financials
